Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
01/12/2016 | Arno Therapeutics, Inc | ARNI | Grant | Stock Option (right to buy) | 88.6k | $0.30 | $26.6k | | 01/12/2016 |
01/04/2016 | EAGLE PHARMACEUTICALS, INC. | EGRX | Grant | Stock Option (right to buy) | 15k | $86.15 | $1.3M | | 01/04/2016 |
04/21/2015 | EAGLE PHARMACEUTICALS, INC. | EGRX | Grant | Stock Option (right to buy) | 10k | $59.31 | $593.1k | | 04/21/2015 |
03/13/2015 | EAGLE PHARMACEUTICALS, INC. | EGRX | Grant | Option (right to buy) | 5k | $46.09 | $230.4k | | 03/13/2015 |
04/08/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Grant | Stock Option (right to buy) | 4.7k | $12.67 | $59.3k | | 04/08/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 9.4k | $0.00 | $0 | By ProQuest Management LLC Plans | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 62.6k | $0.00 | $0 | By ProQuest Management LLC Plans | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Purchase | Common Stock, $0.001 par value | 333.3k | $15.00 | $5M | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series A Convertible Preferred Stock | 1.9M | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series B Convertible Preferred Stock | 1M | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series B-1 Convertible Preferred Stock | 850.5k | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series C Convertible Preferred Stock | 569.5k | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Exercise (in-the-money or at-the-money) | Series C Warrants | 98.4k | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series B-1 Convertible Preferred Stock | 62.6k | $0.00 | $0 | By ProQuest Management LLC Plans | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Series C Convertible Preferred Stock | 9.4k | $0.00 | $0 | By ProQuest Management LLC Plans | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Exercise (in-the-money or at-the-money) | Series C Warrants | 1.6k | $0.00 | $0 | By ProQuest Management LLC Plans | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 569.5k | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 850.5k | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 1M | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |
02/18/2014 | EAGLE PHARMACEUTICALS, INC. | EGRX | Conversion | Common Stock, $0.001 par value | 1.9M | $0.00 | $0 | By ProQuest Investments IV, L.P. | 02/18/2014 |